Jade Biosciences opened lower at $16.44, compared with its previous close of $16.54. In the last trading session, the stock traded between $15.60 and $16.64. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 2 years ago in Jade Biosciences is now worth
$ 156.46
Giving a profit of
$ 56.46 (56.46%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 8 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.68 (-4.08%)
Day High
$16.64
Day Low
$15.60
Day Open
$16.44
Prev Close
$16.54
Volume
7,22,821
1W Return
5.35%
1M Return
13.23%
3M Return
-28.94%
6M Return
-36.18%
1Y Return
61.89%
Fundamentals
Market Cap ($ Mn)
1,009
PE Ratio
-
PB Ratio
3.01
PEG Ratio
-
ROE
-109.25%
ROCE
-82.73%
EPS (TTM)
-
Investment Returns
1 Week
5.35%
1 Month
13.23%
3 Months
-28.94%
6 Months
-36.18%
9 Months
5.35%
Financials
Quarterly
All values in $ Mn
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Jun 26
Updates
1Oct
HC Wainwright reiterates Buy on Jade Biosciences, holds $55 target
HC Wainwright & Co. reiterated a Buy rating on Jade Biosciences (JBIO). Analyst Arthur He maintained a price target of $55. The rating action signals sustained confidence in the company's outlook.
Jade Biosciences missed Q2 EPS estimates with a loss of $(0.76) per share versus a $(0.64) forecast. The result marks an 18.75% miss and an 11.63% increase in losses compared to the prior year's $(0.86) per share.
3mo ago
26Jun
Jade Biosciences appoints Dr. Mark Eisner to Board of Directors
Jade Biosciences appointed Dr. Mark Eisner to its Board of Directors, effective June 25, 2026. Dr. Eisner brings over 25 years of experience in clinical development and immunology. His appointment aims to support the advancement of Jade's pipeline of antibody-based therapies for autoimmune diseases.
4mo ago
15Jun
UBS initiates coverage on Jade Biosciences with Buy rating
UBS analyst Michael Yee has initiated coverage on Jade Biosciences with a Buy rating and a price target of $45.
